Mark Samuels

Mark Samuels is the Chief Executive Officer of the British Generic Manufacturers Association (BGMA), a position he has held since December 2020. In this role, he represents the interests of the generic medicines industry, which supplies a significant portion of medications used by the National Health Service (NHS) in the UK, accounting for four out of five prescriptions.36

Background and Experience

Samuels has a strong background in the pharmaceutical and medical device sectors. Prior to his role at BGMA, he was involved in various leadership positions, including as CEO and co-founder of SpectRX, Inc., where he played a key role in driving the company’s valuation to nearly $200 million following a successful IPO on NASDAQ. He also established strategic partnerships with major companies such as Abbott Laboratories and Roche Diagnostics.1

In addition to his experience in the generic medicines sector, Samuels has been recognized for his contributions to medical technology, holding numerous patents and receiving an Emmy for technical innovation. He is a graduate of the Georgia Institute of Technology, where he earned both a Bachelor of Science in Physics and a Master of Science.14

Current Role and Impact

As CEO of BGMA, Samuels focuses on advocating for policies that support the generic medicines industry and enhancing the public's understanding of its importance. He has emphasized the critical role that investment in scientific knowledge plays in driving Britain's global impact in healthcare.25 His leadership is pivotal as the industry navigates challenges and opportunities in the evolving landscape of healthcare and pharmaceuticals.6